What is the diagnosis for a patient with positive Hepatitis B (HBV) surface antigen, negative HBV surface antibody, positive HBV core antibody (HBcAb) Immunoglobulin G (IgG), negative HBV core antibody IgM, positive Hepatitis B e-antigen (HBeAg), and positive Hepatitis B e-antibody (HBeAb), who is asymptomatic and has a history of blood transfusions?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Chronic Hepatitis B with Positive HBeAg and HBeAb

This patient has chronic hepatitis B infection, most likely in a transitional phase between immune-active and inactive disease, given the unusual coexistence of both HBeAg and HBeAb positivity. The key to determining whether this represents chronic inactive hepatitis (Choice D) versus chronic active hepatitis requires HBV DNA quantification, which is not provided in this case.

Serologic Pattern Analysis

The patient's serologic profile demonstrates:

  • HBsAg positive = Active HBV infection 1
  • HBsAb negative = Not immune/recovered 1
  • HBcAb IgG positive = Past or chronic infection 1
  • HBcAb IgM negative = Rules out acute infection 1
  • HBeAg positive AND HBeAb positive = Unusual transitional state 2

This pattern definitively excludes:

  • Choice A (HBV Immunity): Requires HBsAg negative and HBsAb positive 1, 3
  • Choice B (Acute infection): Requires HBcAb IgM positive, which this patient lacks 1
  • Choice C (Resolved infection): Requires HBsAg negative with anti-HBc and anti-HBs positive 1

Chronic HBV Infection Classification

The persistence of HBsAg for more than 6 months defines chronic HBV infection 1. Given the patient's history of blood transfusion 10 years ago and current asymptomatic status with normal liver enzymes, this represents chronic infection 1.

The critical distinction between chronic inactive hepatitis (inactive carrier) and chronic active hepatitis depends on:

Inactive HBsAg Carrier State Criteria 1:

  • HBsAg positive ≥6 months
  • HBeAg negative, anti-HBe positive
  • Serum HBV DNA <10^5 copies/mL (or <2,000 IU/mL per newer guidelines) 1, 3
  • Persistently normal ALT/AST levels

Chronic Active Hepatitis Criteria 1:

  • HBsAg positive ≥6 months
  • HBV DNA >20,000 IU/mL (HBeAg-positive) or >2,000 IU/mL (HBeAg-negative)
  • Elevated ALT/AST levels

The Unusual HBeAg/HBeAb Coexistence

The simultaneous presence of both HBeAg and HBeAb is rare but documented 2. This pattern typically represents:

  • A transitional phase during HBeAg seroconversion 1
  • Possible infection with multiple HBV strains or mutants 4
  • An unstable immunologic state 2

Clinical Decision Algorithm

Given this patient's presentation:

  1. Normal ALT/AST = Favors inactive carrier state 1
  2. Asymptomatic status = Consistent with inactive phase 1
  3. 10-year history = Suggests established chronic infection 1
  4. Coexistent HBeAg/HBeAb = Requires HBV DNA quantification to classify definitively 1, 3

Without HBV DNA levels, the most appropriate answer is Choice D (Chronic INACTIVE hepatitis) based on:

  • Normal liver enzymes (ALT, AST, ALP) 1
  • Asymptomatic presentation 1
  • Long-standing infection (10 years) 1

Critical Next Steps

HBV DNA quantification is mandatory to confirm inactive carrier status versus chronic active hepatitis 1, 3. The threshold is:

  • <2,000 IU/mL = Inactive carrier 1, 3
  • ≥2,000 IU/mL = Chronic active hepatitis requiring treatment consideration 1, 3

Serial ALT monitoring every 3-4 months for at least one year is recommended to detect fluctuations that might indicate HBeAg-negative chronic active hepatitis 3.

Important Caveats

  • The coexistence of HBeAg and HBeAb can occur during seroconversion or with precore/core promoter mutants 4, 2
  • Patients with inactive carrier state can reactivate to active hepatitis, requiring ongoing surveillance 1
  • Despite normal enzymes, these patients remain at risk for hepatocellular carcinoma and require long-term monitoring 1
  • Immunosuppression can trigger HBV reactivation even in inactive carriers 1, 5

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Hepatitis B Serology Interpretation

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Diagnosis of hepatitis B virus infection through serological and virological markers.

Expert review of gastroenterology & hepatology, 2008

Guideline

Interpretation of Hepatitis B Surface Antigen Non-reactive & Reactive Hepatitis B Core Antibody

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.